Search
-
GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme
Media
Data support progression to phase III clinical trials.
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-data-from-phase-ii-seasonal-influenza-mrna-vaccine-programme/
First published: 12 September 2024
-
GlaxoSmithKline update: A (H1N1) influenza vaccine development
Media
GSK has received orders from several governments aiming to stockpile a H1N1 adjuvanted influenza vaccine as a precautionary measure.
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-a-h1n1-influenza-vaccine-development/
First published: 14 May 2009
-
GlaxoSmithKline update: A (H1N1) influenza
Media
WHO raises influenza pandemic alert to phase 6
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-a-h1n1-influenza/
First published: 11 June 2009
-
H5N1 vaccine approved by the U.S. FDA as pandemic influenza preparedness measure
Media
GSK announced FDA has approved its pandemic Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted for the immunisation of adults 18+.
https://www.gsk.com/en-gb/media/press-releases/h5n1-vaccine-approved-by-the-us-fda-as-pandemic-influenza-preparedness-measure/
First published: 25 November 2013
-
Pandemic (H1N1) 2009 influenza update
Media
GSK issued an update on H1N1 influenza virus vaccine, it's commenced the clinical development programme for its adjuvanted pandemic vaccine.
https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update/
First published: 13 August 2009
-
FDA Approves GlaxoSmithKline’s four-strain seasonal influenza vaccine for use in the US
Media
GSK announced ,FDA has approved FLUARIX QUADRIVALENT Influenza Vaccine for the immunisation of patients to help prevent seasonal influenza
https://www.gsk.com/en-gb/media/press-releases/fda-approves-glaxosmithkline-s-four-strain-seasonal-influenza-vaccine-for-use-in-the-us/
First published: 17 December 2012
-
GSK announces first four-strain seasonal influenza vaccine granted marketing authorisation in Germany and the UK
Media
GSK has announced the marketing authorisation of its quadrivalent (four-strain) influenza vaccine in Germany and the UK.
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-four-strain-seasonal-influenza-vaccine-granted-marketing-authorisation-in-germany-and-the-uk/
First published: 03 April 2013
-
Pandemic 2009 Influenza Update: US FDA approves GSK’s pandemic H1N1 vaccine
Media
GSK today announced that FDA has approved a sBLA for its unadjuvanted influenza A (H1N1) pandemic vaccine.
https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-us-fda-approves-gsk-s-pandemic-h1n1-vaccine/
First published: 09 November 2009
-
New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age
Media
New data published in The Lancet from a Phase III clinical trial with Fluarix Tetra which prevented influenza in children 6 to 35 months
https://www.gsk.com/en-gb/media/press-releases/new-clinical-data-demonstrate-high-vaccine-efficacy-of-fluarix-tetra-influenza-vaccine-in-children-6-35-months-of-age/
First published: 06 March 2018
-
Landmark New England Journal of Medicine publication reinforces potential of GSK’s respiratory syncytial virus older adult vaccine candidate
Media
First peer-reviewed publication of phase III RSV vaccine data in older adults, including those with comorbidities who are most at risk.
https://www.gsk.com/en-gb/media/press-releases/nejm-publication-reinforces-potential-of-gsk-s-respiratory-syncytial-virus-older-adult-vaccine-candidate/
First published: 15 February 2023